RMS Appoints John Toomey as VP of Growth & Innovation

CHESTER, NY – June 14, 2019 – Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS Medical”) today announced the appointment of John Toomey to the newly created position of Vice President of Growth and Innovation. Mr. Toomey brings to RMS over 30 years of medical device industry experience as an executive, patent … Continued

RMS Medical Products Appoints Healthcare Industry Veteran R. John Fletcher to Board of Directors

Former Chairman of Spectranetics Corporation; NACD 2018 Director of the Year CHESTER, N.Y.–(BUSINESS WIRE)– Repro Med Systems, Inc. dba RMS Medical Products (OTCQX:REPR) (“RMS Medical”) announced that R. John Fletcher has been appointed as an independent member of RMS Medical’s Board of Directors. With this appointment, RMS Medical’s Board of Directors fills the vacancy created … Continued

RMS Gives PI Patients a Voice Through Social Media Campaign

Chester, NY – As April comes to a close, so does the 9th World Primary Immunodeficiency (PI) Week campaign, which took place April 22 – 29, 2019. April is also Primary Immunodeficiency Awareness Month. This years’ World PI Week theme put the spotlight on patient care. In our effort to help spread awareness, we (the … Continued

RMS Medical Products Announces Voting Results from Annual Meeting of Shareholders

Kathy S. Frommer Elected to the Board of Directors CHESTER, N.Y.–(BUSINESS WIRE)– Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS Medical”) today announced that shareholders voted in favor of all items of business put forth at the company’s Annual Meeting of Shareholders held on April 23, 2019 in Chester, NY. Shareholders elected director nominee … Continued

REPR 2018 Shareholders Meeting

Operating Highlights Record net revenues – up 12.4% Gross margin increased by 230 bps Higher income and Adjusted EBITDA Strong balance sheet with no debt and simple capital structure Refreshed and strengthened management team Added significant talent to the Board February 2019: strategic plan launched to become the preferred drug delivery partner for specific infusion … Continued

February 2019 Investor Presentation

Presentation Highlights:  Refreshed, strengthened management team Established strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets Net Revenue increased 12.4% to $17.4 million from $15.4 million Adjusted EBITDA* expanded to $2.7 million, up 73.9% from $1.6 million in 2017 This presentation contains forward looking statements that involve risks … Continued

Fourth Quarter 2018 Results Conference Call

Conference Call Highlights:  Refreshed, strengthened management team Established strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets Net Revenue increased 12.4% to $17.4 million from $15.4 million Adjusted EBITDA* expanded to $2.7 million, up 73.9% from $1.6 million in 2017 This presentation contains forward-looking statements that involve risks … Continued

REPR November Investor Presentation – 11.13.18

Presentation Highlights: Net Sales increased 18.1% to $4.5 million Gross margin improved to 63.6% compared to 61.8% Net income grew to $386,553; 8.5% of net sales Don Pettigrew was appointed to President and Chief Commercial Officer on Spetmber 4th, 2018   This presentation contains forward-looking statements that involve risks and uncertainties, including but not limited … Continued